GK
NVO

Graney & King’s Novo Nordisk NVO Stock Holding History

Graney & King’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.35K Hold
200
– – ﹤0.01% 255
2025
Q4 		$10.2K Sell
200
-415
-67% -$21.2K 0.01% 237
2025
Q3 		$34.1K Buy
615
+3
+0.5% +$176 0.02% 158
2025
Q2 		$42.2K Buy
612
+5
+0.8% +$340 0.03% 140
2025
Q1 		$42.1K Hold
607
– – 0.03% 134
2024
Q4 		$52.2K Buy
+607
New +$65.6K 0.04% 117

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Graney & King's NVO Position: Q1 2026 in Review

Graney & King held its Novo Nordisk (NVO) position steady in Q1 2026 at 200 shares worth $7.35K. The position accounts for ﹤0.01% of the portfolio, ranked #255.

Graney & King first reported a position in NVO in Q4 2024 and has held it in 6 quarters since. The position peaked at $52.2K in Q4 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Graney & King held 200 shares of Novo Nordisk worth $7.35K as of Q1 2026.
  • Graney & King left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of Graney & King's portfolio in Q1 2026, its #255 holding.
  • Graney & King first reported a position in Novo Nordisk in Q4 2024 and has held it in 6 quarters since.
  • Graney & King's Novo Nordisk position peaked at $52.2K in Q4 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Graney & King's 13F filing for Q1 2026, filed 18 May 2026.